Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Generic Spikevax COVID-19 mRNA Vaccine 0.5ml inj vials
1404000ATAAAGAG
|
Coronavirus vaccine | Coronavirus vaccine | Immunological Products and Vaccines | No data available |
|
Generic Spikevax JN.1 COVID-19 mRNA Vacc 0.1mg/ml inj md
1404000ATAABRBR
|
Coronavirus vaccine | Coronavirus vaccine | Immunological Products and Vaccines | No data available |
|
Generic Spikevax JN.1 COVID-19 mRNA Vacc 0.5ml dose inj pfs
1404000ATAABWBW
|
Coronavirus vaccine | Coronavirus vaccine | Immunological Products and Vaccines | No data available |
|
Generic Spikevax XBB.1.5 COVID-19 Vacc 0.1mg/1ml inj md
1404000ATAABKBK
|
Coronavirus vaccine | Coronavirus vaccine | Immunological Products and Vaccines | No data available |
|
Nuvaxovid JN.1 COVID-19 Vaccine 0.5ml dispersion inj vials
1404000ATBEACBY
|
COVID-19 Novavax | Coronavirus vaccine | Immunological Products and Vaccines | No data available |
|
Nuvaxovid JN.1 COVID-19 Vaccine 0.5ml dose inj pfs
1404000ATBEADCD
|
COVID-19 Novavax | Coronavirus vaccine | Immunological Products and Vaccines | No data available |
|
Nuvaxovid XBB.1.5 COVID-19 Vaccine 0.5ml inj multidose vials
1404000ATBEABBP
|
COVID-19 Novavax | Coronavirus vaccine | Immunological Products and Vaccines | No data available |
|
Spikevax COVID-19 mRNA Vaccine 0.5ml inj multidose vials
1404000ATBHAAAG
|
Spikevax | Coronavirus vaccine | Immunological Products and Vaccines | No data available |
|
Spikevax JN.1 COVID-19 Vacc 0.1mg/ml inj md vials
1404000ATBHAEBR
|
Spikevax | Coronavirus vaccine | Immunological Products and Vaccines | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.